縱橫遊控股(08069.HK)出售合共864萬股加達控股股份
格隆匯7月16日丨縱橫遊控股(08069.HK)公佈,於2021年7月16日,公司已接納對公司持有的3413萬股加達控股(01620.HK)股份的股份要約,股份要約價為每股加達控股股份0.2278港元。
於股份要約前,公司於2021年6月15日至6月17日期間進行的一連串交易中,於市場上出售合共864萬股加達控股股份,平均價格為每股加達控股股份約0.2443港元,所得款項總額合共約為210萬港元。
股份要約及先前出售事項旨在讓集團變現其證券投資及提升集團的流動資金。集團擬將股份要約及先前出售事項的所得款項用作日常營運資金用途及於其他行業作潛在業務多元化發展,以擴大其收益及收入來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.